Associated Papers
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
39338204 (PubMed )
Supplement: jpm-14-00950-s001.zip › Supplementary_Table_S5.xlsx › Supplementary_Table_S5.
HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer.
Mishra R et al.
Molecular Carcinogenesis, 2024
HER3 Alterations in Cancer and Potential Clinical Implications.
Kilroy MK et al.
Cancers, 2022
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2
ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
Kiavue N et al.
Oncogene, 2020
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
Umelo I et al.
Oncotarget, 2016
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
Select a paper to view details